Catalyst Pharmaceuticals

Catalyst is developing amifampridine phosphate for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that amifampridine phosphate has the potential to treat other neuromuscular disorders such as congenital myasthenic syndromes and some cases of myasthenia gravis that are refractory to currently approved therapies.
Type
Public
HQ
Coral Gables, US
Founded
2002
Employees
23 (est)
Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, US

Catalyst Pharmaceuticals Locations

Coral Gables, US

Catalyst Pharmaceuticals Metrics

Catalyst Pharmaceuticals Summary

Market capitalization

$95.3 M

Closing share price

$1.15
Catalyst Pharmaceuticals's latest market capitalization is $95.3 M.

Catalyst Pharmaceuticals Market Value History

Catalyst Pharmaceuticals News

Catalyst Pharmaceuticals Company Life

You may also be interested in